We are in the midst of a North American epidemic of obesity and type 2 diabetes. Since patients with psychiatric disorders who receive psychopharmacologic treatments may be at even greater risk than the general population for weight gain, dyslipidemia, and diabetes and their complications, psychopharmacologists now need standards for how to monitor and manage these risks.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/12523866